rs761396172
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PVS1_ModeratePM2PP5_Very_Strong
The NM_004482.4(GALNT3):c.516-2A>T variant causes a splice acceptor, intron change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000118 in 1,613,006 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_004482.4 splice_acceptor, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 12 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GALNT3 | NM_004482.4 | c.516-2A>T | splice_acceptor_variant, intron_variant | ENST00000392701.8 | NP_004473.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GALNT3 | ENST00000392701.8 | c.516-2A>T | splice_acceptor_variant, intron_variant | 1 | NM_004482.4 | ENSP00000376465.3 | ||||
GALNT3 | ENST00000412248.5 | c.516-2A>T | splice_acceptor_variant, intron_variant | 5 | ENSP00000412643.1 |
Frequencies
GnomAD3 genomes AF: 0.0000723 AC: 11AN: 152224Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000279 AC: 7AN: 250868Hom.: 0 AF XY: 0.0000221 AC XY: 3AN XY: 135600
GnomAD4 exome AF: 0.00000548 AC: 8AN: 1460782Hom.: 0 Cov.: 32 AF XY: 0.00000688 AC XY: 5AN XY: 726768
GnomAD4 genome AF: 0.0000723 AC: 11AN: 152224Hom.: 0 Cov.: 33 AF XY: 0.0000538 AC XY: 4AN XY: 74370
ClinVar
Submissions by phenotype
Tumoral calcinosis, hyperphosphatemic, familial, 1 Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Apr 25, 2022 | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Jan 01, 2008 | - - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 14, 2023 | This sequence change affects an acceptor splice site in intron 2 of the GALNT3 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in GALNT3 are known to be pathogenic (PMID: 15133511, 20358599). This variant is present in population databases (no rsID available, gnomAD 0.04%). Disruption of this splice site has been observed in individual(s) with tumoral calcinosis (PMID: 15687324, 27164190). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. This variant is also known as IVS1-2a>t. ClinVar contains an entry for this variant (Variation ID: 7794). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Mar 22, 2024 | Canonical splice site that results in a null allele in a gene for which loss of function is a known mechanism of disease (PMID: 18618993); This variant is associated with the following publications: (PMID: 25525159, 18618993, 27164190, 29625052, 15687324) - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at